Regado Biosciences, Inc., a private biopharmaceutical company leading the development of antithrombotic aptamers with matched active control agents, announced today that it has received funding from the United States government under the Qualifying Therapeutic Discovery Project (QTDP) grants program to advance the development of the company's three programs, REG1, REG2 and REG3. The total grant amount allocated to Regado was more than $733,000.
The QTDP program is part of the Patient Protection and Affordable Care Act signed into law in March 2010. It states that qualified discovery projects must involve scientific activities that are designed to treat areas of unmet medical need. The QTDP grant program provides support for innovative projects that are determined by the U.S. Department of Health and Human Services to have reasonable potential to result in a new therapy to treat chronic and acute diseases, reduce health care costs or represent a significant advance in U.S. competitiveness in the fields of life, biological and medical sciences.
"We are extremely pleased that our focus and efforts towards developing a new and innovative therapeutic technology of proprietary controllable aptamer drug systems has been recognized favorably by the federal government," said David J. Mazzo, PhD, President and CEO of Regado. "We will use these funds to advance our company's extensive pipeline for the treatment of cardiovascular diseases."
The New Picus® 2 sets a new standard for connected electronic pipettes